JP2019507185A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507185A5
JP2019507185A5 JP2018559177A JP2018559177A JP2019507185A5 JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5 JP 2018559177 A JP2018559177 A JP 2018559177A JP 2018559177 A JP2018559177 A JP 2018559177A JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
phenyl
membered heterocyclic
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018559177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507185A (ja
JP7098214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015749 external-priority patent/WO2017136309A1/en
Publication of JP2019507185A publication Critical patent/JP2019507185A/ja
Publication of JP2019507185A5 publication Critical patent/JP2019507185A5/ja
Application granted granted Critical
Publication of JP7098214B2 publication Critical patent/JP7098214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018559177A 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用 Active JP7098214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662289463P 2016-02-01 2016-02-01
US62/289,463 2016-02-01
US201662398872P 2016-09-23 2016-09-23
US62/398,872 2016-09-23
PCT/US2017/015749 WO2017136309A1 (en) 2016-02-01 2017-01-31 USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Publications (3)

Publication Number Publication Date
JP2019507185A JP2019507185A (ja) 2019-03-14
JP2019507185A5 true JP2019507185A5 (enExample) 2020-03-12
JP7098214B2 JP7098214B2 (ja) 2022-07-11

Family

ID=58018271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559177A Active JP7098214B2 (ja) 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用

Country Status (11)

Country Link
US (1) US11357777B2 (enExample)
EP (1) EP3411026B1 (enExample)
JP (1) JP7098214B2 (enExample)
KR (1) KR20180104123A (enExample)
CN (2) CN116726178A (enExample)
AU (1) AU2017216429B2 (enExample)
BR (1) BR112018015718A2 (enExample)
CA (1) CA3012001A1 (enExample)
IL (1) IL260701B (enExample)
MX (1) MX386216B (enExample)
WO (1) WO2017136309A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844064B2 (en) * 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
US11357777B2 (en) 2016-02-01 2022-06-14 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
US12220414B2 (en) * 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
AU2019301887A1 (en) * 2018-07-12 2021-01-07 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2021073643A1 (zh) * 2019-10-18 2021-04-22 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CA3170507A1 (en) * 2020-02-21 2021-08-26 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
CN118525022A (zh) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
CN102164320B (zh) 2011-04-11 2016-06-22 北京数字太和科技有限责任公司 一种改进的基于条件接收技术的终端
ES2911276T3 (es) * 2013-03-15 2022-05-18 Cyclerion Therapeutics Inc Estimuladores de sGC
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US9663527B2 (en) * 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
AU2015292833B2 (en) * 2014-07-22 2019-11-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
BR112018011154B1 (pt) * 2015-11-30 2023-09-26 Cyclerion Therapeutics, Inc Dispersões sólidas compreendendo um estimulador de sgc
US11357777B2 (en) 2016-02-01 2022-06-14 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

Similar Documents

Publication Publication Date Title
DK2041102T3 (en) Inhibitors of human protein tyrosine phosphatase and methods of use
AU2006245676B2 (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
IL186750A (en) Patridines, their uses in preparing HCV replication inhibitors, their compositions and combinations
JP2009534425A5 (enExample)
JP2019502686A5 (enExample)
IL268751B (en) Pharmaceutical preparations for combined treatment
JP2018501276A5 (enExample)
RU2002129569A (ru) Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора
JP2008509187A5 (enExample)
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
RU2009121775A (ru) Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное
RU2002111005A (ru) Производные нафтиридина
JP2003515523A5 (enExample)
RU2006136881A (ru) Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv
RU2008141511A (ru) Конденсированные гетероциклические соединения и их применение в качестве модуляторов mglur5
JP2016512547A (ja) 線維症疾患の治療のための化合物
JP2024507414A5 (enExample)
AU2005282290B2 (en) Combination of organic compounds
KR20180104123A (ko) 비알콜성 지방간염 (NASH)의 치료를 위한 sGC 자극제의 용도
JP2021518379A5 (enExample)
WO2010000030A1 (en) Thiazopyrimidinones and uses thereof
WO2005102346A2 (en) Use of c-kit inhibitors for treating fibrosis
RU2014105177A (ru) Новое соединение, проявляющее ингибиторную активность в отношении parp
CN112384214A (zh) 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑
US20080004279A1 (en) Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases